Transforming growth factor-ß as a therapeutic target for the cardiac damage of Chagas disease.
Mariana Caldas WaghabiRoberto Rodrigues FerreiraRayane da Silva AbreuWim DegraveElen Mello de SouzaSabine BaillyJean-Jacques FeigeTania C de Araújo-JorgePublished in: Memorias do Instituto Oswaldo Cruz (2022)
Transforming growth factor beta (TGF-β) is deeply involved on the pathogenesis of Chagas disease. Our group has been investigating the participation of this pleiotropic cytokine in different aspects of Chagas disease over the last 20 years. Important observations have been made, such as: (i) the ability of Trypanosoma cruzi in activating latent TGF-β; (ii) the potential involvement of TGF-β pathway on T. cruzi invasion of host cells; (iii) association of TGF-β with parasite intracellular replication; (iv) cardiac fibrosis development and maintenance; (v) disruption of Connexin-43 plaque structures and (vi) inflammation and immune response. In this perspective article we intend to discuss the advances of the potential use of new therapies targeting TGF-β to treat the cardiac alterations of Chagas disease-affected patients.
Keyphrases
- transforming growth factor
- epithelial mesenchymal transition
- trypanosoma cruzi
- immune response
- left ventricular
- oxidative stress
- end stage renal disease
- induced apoptosis
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- high resolution
- heart failure
- cell cycle arrest
- inflammatory response
- endoplasmic reticulum stress
- drug delivery
- reactive oxygen species
- patient reported outcomes
- mass spectrometry
- plasmodium falciparum
- patient reported